China Biopharmaceuticals (01177): KYLO-0603 "THR- small molecule agonist" announced Phase I clinical data at EASL 2026.

The Zhitong Finance APP reports that China Biopharmaceutical Group (01177) has announced that its wholly-owned subsidiary Hangzhou Hegia Biopharmaceutical Co., Ltd. (Hegia) has independently developed the Class 1 innovative drug Kylo-0603 "THR- Small Molecule Agonist". The first phase I clinical trial data in healthy subjects was presented at the 2026 European Association for the Study of the Liver (EASL) Annual Meeting.